Meropenem/Vaborbactam

  • Brand Name : Vabomere
  • Drug Class : Carbapenems
  • Medical Author : John P. Cunha, DO, FACOEP
  • Medical Reviewer :
  • _eael_post_view_count : 10

What Is Meropenem/Vaborbactam and How Does It Work?

Meropenem/vaborbactam is used for complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in adults 18 years and older.

Meropenem/vaborbactam is available under the following different brand names: Vabomere.

What Are the Dosages of Meropenem/Vaborbactam?

Dosages of Meropenem/Vaborbactam:

Dosage Forms and Strengths

Injection, Sterile Powder for Reconstitution

  • (1g/1g)/vial: 2 g

Dosage Considerations – Should be Given as Follows:

Urinary Tract Infections

  • Indicated for complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in adults 18 years and older
  • 4 g (meropenem [2g]/vaborbactam [2g]) intravenously (IV) every 8 hours for up to 14 days; infuse over 3 hours

Dosage Modifications

Renal impairment

  • Treatment duration for all doses: Up to 14 days
  • eCrCl greater than 50 mL/min/1.73²: No dosage adjustment necessary
  • eCrCl 30-49 mL/min/1.73²: 2 g (meropenem [1g]/vaborbactam [1g]) IV every 8 hours
  • eCrCl 15-29 mL/min/1.73²: 2 g (meropenem [1g]/vaborbactam [1g]) IV every 12 hours
  • eCrCl less than 15 mL/min/1.73²: 1 g (meropenem [0.5g]/vaborbactam [0.5g]) IV every 12 hours
  • Dose adjustments for renal impairment should be administered after hemodialysis session

Dosing Considerations

  • Meropenem is known to be substantially excreted by the kidneys, and the risk of adverse reactions may be greater in patients with renal impairment
  • Geriatric patients are more likely to have decreased renal function; use caution in dose selection and monitor if necessary
  • Children under 18 years: Safety and efficacy not established

Add to cart